UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 643

Sortiert nach

Height, weight, and motor–social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy

Human reproduction (Oxford), 2004-06, Vol.19 (6), p.1323-1330

2004

Volltextzugriff (PDF)

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

Metabolism, clinical and experimental, 2003-07, Vol.52 (7), p.908-915

2003

Volltextzugriff (PDF)

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

Fertility and sterility, 2002-03, Vol.77 (3), p.520-525

2002

Volltextzugriff (PDF)

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

Fertility and sterility, 2001, Vol.75 (1), p.46-52

2001

Volltextzugriff (PDF)

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy

Human reproduction (Oxford), 2004-03, Vol.19 (3), p.510-521

2004

Volltextzugriff (PDF)

Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome

Diabetic medicine, 2004-08, Vol.21 (8), p.829-836

2004

Volltextzugriff (PDF)

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS)

Journal of adolescent health, 2001-09, Vol.29 (3), p.160-169

2001

Volltextzugriff (PDF)

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome

Metabolism, clinical and experimental, 1999-04, Vol.48 (4), p.511-519

1999

Volltextzugriff (PDF)

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

Metabolism, clinical and experimental, 1994-05, Vol.43 (5), p.647-654

1994

Volltextzugriff (PDF)

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30

Metabolism, clinical and experimental, 2001-07, Vol.50 (7), p.856-861

2001

Volltextzugriff (PDF)

Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

Metabolism, clinical and experimental, 1999-12, Vol.48 (12), p.1589-1595

1999

Volltextzugriff (PDF)

Thrombophilia and hypofibrinolysis : Pathophysiologies of osteonecrosis

Clinical orthopaedics and related research, 1997, Vol.334 (334), p.43-56

1997

Volltextzugriff (PDF)

Hypofibrinolysis, thrombophilia, osteonecrosis

Clinical orthopaedics and related research, 2001-05, Vol.386 (386), p.19-33

2001

Volltextzugriff (PDF)

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications

Metabolism, clinical and experimental, 2000-07, Vol.49 (7), p.845-852

2000

Volltextzugriff (PDF)

Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease

Journal of bone and joint surgery. American volume, 1996-01, Vol.78 (1), p.3

1996

Volltextzugriff (PDF)

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

Human reproduction (Oxford), 2002-11, Vol.17 (11), p.2858-2864

2002

Volltextzugriff (PDF)

Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease

Clinical orthopaedics and related research, 1998-07, Vol.352 (352), p.159-167

1998

Volltextzugriff (PDF)

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

Metabolism, clinical and experimental, 1997-04, Vol.46 (4), p.454-457

1997

Volltextzugriff (PDF)

The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis

Clinical orthopaedics and related research, 1999-09, Vol.366 (366), p.133-146

1999

Volltextzugriff (PDF)

Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage

Fertility and sterility, 2000-08, Vol.74 (2), p.394-397

2000

Volltextzugriff (PDF)

Risk factors for osteonecrosis in systemic lupus erythematosus

Journal of rheumatology, 1997-04, Vol.24 (4), p.654

1997

Volltextzugriff (PDF)

Hypofibrinolysis: A common, major cause of osteonecrosis

American journal of hematology, 1994-02, Vol.45 (2), p.156-166

1994

Volltextzugriff (PDF)

Resistance to activated protein C and Legg-Perthes disease

Clinical orthopaedics and related research, 1997-05, Vol.338 (338), p.139-152

1997

Volltextzugriff (PDF)

Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients

The American journal of cardiology, 1995-01, Vol.75 (2), p.132-136

1995

Volltextzugriff (PDF)

Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V leiden mutation (resistance to activated protein C)

The American journal of cardiology, 1999-09, Vol.84 (5), p.549-554

1999

Volltextzugriff (PDF)

1 – 25 von 643

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(569)
Mit Volltextzugriff
(492)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Height, weight, and motor–social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy

Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS)

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30

Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome

Thrombophilia and hypofibrinolysis : Pathophysiologies of osteonecrosis

Hypofibrinolysis, thrombophilia, osteonecrosis

The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications

Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis

Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage

Risk factors for osteonecrosis in systemic lupus erythematosus

Hypofibrinolysis: A common, major cause of osteonecrosis

Resistance to activated protein C and Legg-Perthes disease

Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients

Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V leiden mutation (resistance to activated protein C)

Suchergebnisse filtern